10.1007/s00277-018-3418-2 - Multicenter phase 1/2 study of forode...

This document has been corrected

Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma

10.1007/s00277-018-3418-2

Published Online: 2018-07-05

Journal: Annals of Hematology•Publisher: Springer Science and Business Media LLC

Authors: Dai Maruyama•Hirohiko Shibayama•Hirokazu Nagai•Isao Yoshida•Junji Suzumiya•Kazuo Tamura•Kensei Tobinai•Kiyohiko Hatake•Kiyoshi Ando•Kunihiro Tsukasaki•Masafumi Taniwaki•Michihiro Hidaka•Mitsutoshi Kurosawa•Norifumi Tsukamoto•Ryuzo Ueda•Takahiro Yamauchi•Tohru Murayama•Toshiki Uchida•Yoko Okitsu•Yoko Suehiro•Yoshinobu Maeda

This document has been corrected

Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma

10.1007/s00277-018-3418-2

Published Online: 2018-07-05

Journal: Annals of Hematology

NOW

2018-07-27•Correction

Correction to: Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma

10.1007/s00277-018-3455-x

* information provided by CrossRef

2018-07-27•Correction

10.1007/s00277-018-3455-x

* information provided by CrossRef

2018-07-05•Published

2018-07-27•Correction

Correction to: Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma

10.1007/s00277-018-3455-x

* information provided by CrossRef

This document has been corrected

Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma

10.1007/s00277-018-3418-2

Published Online: 2018-07-05

Journal: Annals of Hematology•Publisher: Springer Science and Business Media LLC